Qlife Holding AB AI Stock Analysis
Want to see SE:QLIFE full AI Analyst Report?
Qlife Holding AB (QLIFE) AI Stock Analysis
Qlife Holding AB
(Nasdaq OMX AB:QLIFE)
Extremely weak financials with minimal revenue, negative equity, and cash outflows are the dominant factors. Bearish technical signals from price below DMAs and negative MACD add pressure, while negative P/E further weighs on the score.
Qlife Holding AB (QLIFE) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 27.55M
- Dividend Yield
- ―
- Average Volume (3M)
- 74.73K
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- 1.41
- Revenue Growth
- 142.55%
- EPS Growth
- 73.84%
- Country
- Sweden
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Qlife Holding AB Business Overview & Revenue Model
Company Description
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehen...
How the Company Makes Money
Qlife Holding AB makes money primarily by commercializing its diagnostic platform and the associated consumables used to run tests. The core revenue model typically combines (1) sales or leasing of instrumentation (the analyzer/platform), and (2) rec...
Qlife Holding AB Financial Statement Overview
Summary
Minimal TTM revenue under 1M with negative growth, deeply negative margins, negative equity, high debt, and persistent cash burn signal severe distress and high financial risk.
Income Statement
15Very NegativeBalance Sheet
10Very NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 798.00K | 324.00K | 50.00K | 244.00K | 17.99M | 39.61M |
| Gross Profit | -7.01M | -18.11M | -158.00K | -6.31M | -10.75M | 44.54M |
| EBITDA | -15.76M | -18.11M | -12.46M | -150.50M | -78.05M | -35.13M |
| Net Income | -17.47M | -20.56M | -55.98M | -159.96M | -93.14M | -38.80M |
Balance Sheet | ||||||
| Total Assets | 8.82M | 9.63M | 11.64M | 39.05M | 192.65M | 193.44M |
| Cash, Cash Equivalents and Short-Term Investments | 1.90M | 1.42M | 2.71M | 1.66M | 14.55M | 73.46M |
| Total Debt | 8.17M | 14.44M | 8.70M | 20.25M | 52.44M | 4.72M |
| Total Liabilities | 9.64M | 17.14M | 13.07M | 62.17M | 101.50M | 30.26M |
| Stockholders Equity | -820.00K | -7.51M | -1.43M | -23.12M | 91.15M | 132.50M |
Cash Flow | ||||||
| Free Cash Flow | -8.27M | -21.49M | -54.17M | -62.64M | -90.67M | -52.82M |
| Operating Cash Flow | -15.59M | -21.49M | -37.37M | -41.80M | -47.73M | -26.05M |
| Investing Cash Flow | 0 | 0 | -16.80M | -20.84M | -42.94M | -26.77M |
| Financing Cash Flow | 14.27M | 20.19M | 55.23M | 49.00M | 32.73M | 106.02M |
Qlife Holding AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Negative. The current price of 0.95 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.31, and below the 200-day MA of 1.79, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 42.39 is Neutral, neither overbought nor oversold. The STOCH value of 57.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLIFE.
Qlife Holding AB Peers Comparison
Overall Rating
SE:CEVI83Outperform
SE:SECT.B78Outperform
SE:SEZI55Neutral
SE:ACARIX45Neutral
SE:SCIB40Underperform
SE:QLIFE38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 4.83B | 35.03 | 15.23% | 1.36% | 1.95% | -8.91% | |
| 78Outperform | SEK 62.28B | 97.61 | 30.26% | 0.72% | 13.94% | 5.70% | |
| 55Neutral | SEK 528.24M | -5.42 | -35.44% | ― | 18.56% | 28.11% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | SEK 201.21M | -5.10 | -96.06% | ― | 40.61% | 32.63% | |
| 40Underperform | SEK 130.47M | -0.69 | -415.20% | ― | 54.94% | 47.64% | |
| 38Underperform | SEK 27.55M | -0.71 | 1852.00% | ― | 142.55% | 73.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:QLIFE | Qlife Holding AB | 0.95 | -0.53 | -35.89% | |
| SE:CEVI | CellaVision AB | 202.50 | 48.33 | 31.35% | |
| SE:SEZI | Senzime AB | 3.36 | -1.72 | -33.86% | |
| SE:SCIB | SciBase Holding AB | 9.24 | -9.85 | -51.61% | |
| SE:SECT.B | Sectra AB Class B | 319.20 | 43.80 | 15.90% | |
| SE:ACARIX | Acarix AB | 0.16 | -0.11 | -40.66% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
